Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

CoMentis

Status and phase: Completed; Phase 2

Conditions: Diabetic Macular Edema

Treatments: Drug: mecamylamine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00536692

ATG003-202

Details and patient eligibility

About

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• macular edema due to diabetic retinopathy

Exclusion criteria

• vision loss from other ocular disease
• intraocular surgery within 3 months
• intraocular anti-VEGF or steroids within 3 months
• HbA1c >12

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)